Valneva (NASDAQ:VALN) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright started coverage on shares of Valneva (NASDAQ:VALN) in a research note published on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $18.00 price objective on the stock. HC Wainwright also issued estimates for Valneva’s Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.49) EPS, FY2025 earnings at ($1.12) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $1.73 EPS, FY2028 earnings at $1.68 EPS and FY2029 earnings at $1.98 EPS.

Separately, Guggenheim lowered their price objective on Valneva from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Valneva has an average rating of “Buy” and a consensus price target of $16.00.

Valneva Stock Performance

Shares of Valneva stock opened at $11.19 on Tuesday. The company’s 50 day moving average price is $7.30 and its two-hundred day moving average price is $6.92. The firm has a market capitalization of $952.16 million, a P/E ratio of -11.42 and a beta of 1.77. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $12.25.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. The company had revenue of $54.84 million during the quarter, compared to analysts’ expectations of $46.28 million. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%. On average, equities analysts forecast that Valneva will post 0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Valneva

A number of institutional investors have recently modified their holdings of the company. Marex Group plc bought a new stake in shares of Valneva during the 2nd quarter valued at about $64,000. GAMMA Investing LLC acquired a new position in Valneva in the first quarter valued at approximately $94,000. Wells Fargo & Company MN boosted its holdings in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after buying an additional 30,859 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new stake in shares of Valneva during the 2nd quarter worth approximately $8,240,000. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.